Appointments at Covance, WuXi, INC Research, Catalent and Warnex – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Pfizer, Contract research organization, Corporate governance

Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Covance, WuXi, INC Research, Catalent and Warnex.

Covance ​has hired Douglas Fast​ as scientific director, analytical services. Fast joins Covance from Pfizer. Earlier in his career he worked at GD Searle and Pharmacia, before they became part of Pfizer.

Also, Covance has named Jonathon Koch ​as vice president (VP) and general manager, discovery and translational services. Before being appointed to lead the new unit Koch was general manager of Covance Greenfield site. He has also worked at Charles River and ClinTrials.

Hao Zhou​ has been promoted to chief financial officer of WuXi PharmaTech​. Zhou joined WuXi in May 2009 having spent the previous 11 years at General Electric.

INC Research​ has hired Michael Hamilton ​as senior medical director of its oncology practice. Hamilton has more than 25 years of clinical oncology experience, including 17 years at the National Cancer Institute.

Elliot Berger ​has been named as VP of global marketing and strategy at Catalent Pharma Solutions​. Berger joins from Johnson & Johnson and has also worked at Ernst & Young.

NexMed ​has expanded its scientific advisory board by electing Jack Reynolds ​and Daniel Salomon​. Reynolds worked at Pfizer for 18 years and Salomon is currently medical director of the Center for Organ and Cell Transplantation at Scripps Green Hospital.

Neil Larimer ​has joined Akrimax Pharmaceuticals​ as VP business development and manufacturing alliances. Larimer was previously senior director, North America, sales and marketing at DPT Laboratories.

Warnex ​has appointed Richard Lacombe ​to its board of directors. Lacombe has more than 30 years biopharm experience, including time at contract research organisations (CRO), and most recently worked at BioSyntech.

Anthony Busa Jr ​has been named as CEO of Cedra​. Busa has 34 years of management experience at companies including Esoterix, Medsites and Covance.

Related topics: Markets & Regulations

Related news

Show more

Follow us

Products

View more

Webinars